The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis

Chen, Jie

doi:10.1371/journal.pone.0200909

Cited by 9 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to pathological stage and tumor characteristics, T Stage, M Stage and tumor size group were related to the prognosis of HCC patients with LN metastasis. Wu et al found that tumor size could be used as an independent risk predictor associated with survival in HCC [46] . In combination with T stage, we grouped the patients according to different tumor sizes and obtained similar conclusions.…”

Section: The Establishment Of Different Risk Groups According To the mentioning

confidence: 99%

A practical nomogram from the SEER database to predict the prognosis of hepatocellular carcinoma patients with lymph node metastasis

Zhang

Tao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The presence of lymph node metastases is related to poor survival outcomes in hepatocellular carcinoma patients and because of the reported low probability of lymph node metastasis, research into the prognoses of such patients is difficult to conduct. In this study, we aimed to develop a nomogram model to predict the prognosis of HCC patients with lymph node metastasis and provided a reasonable basis for the choice of follow-up treatment.Methods: HCC patients diagnosed with LN metastasis from 2010 to 2015 were enrolled from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate Cox regression and lasso regression were used to screen prognostic factors. Cox multiple-factor analysis was employed to investigate the independent prognostic factors for survival. The concordance index (C-index) and calibration curve were used to evaluate the predictive performance of our model. The clinical benefit was assessed via decision curve analysis (DCA). The survival was analyzed using Kaplan-Meier method and the differences among survival curves were compared by the log-rank test.Results: Patients were randomized into the training group (944 patients) and the validation group (402 patients) in a 70:30 ratio. Grade, T stage, surgery to the liver, chemotherapy, radiation recode, AFP, fibrosis score, tumor size group, M stage were selected as independent prognostic factors, and we developed nomograms using these variables. The c-indices of the training and validation groups were 0.70 and 0.73, respectively. The calibration curves for probability of survival showed good agreement. The DCA indicated that the nomogram had positive net benefits. Patients were divided into two risk groups according to our model, survival curves were drawn, and the log-rank test was performed, the p-value of which was <0.001.Conclusions: The nomogram can accurately predict the prognosis of HCC patients with lymph nodes metastasis and provide a reasonable basis for treatment.

show abstract

Section: The Establishment Of Different Risk Groups According To the mentioning

confidence: 99%

A practical nomogram from the SEER database to predict the prognosis of hepatocellular carcinoma patients with lymph node metastasis

Zhang

Tao

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Regarding the choice of covariates and development of the model, patients referred for palliative RT often received oncological treatment and blood work before; hence, we included commonly performed biochemical or hematological markers. Clinical experience has shown that patients with lung cancer generally die earlier than patients with other cancers, such as breast cancer 14 , and patients with certain sites of metastases (e.g., bone only) live longer than patients with others, such as brain and spinal metastases with cord compression [32][33][34][35] . Since no data were available on sites of metastatic diseases, we substituted with irradiation data.…”

Section: Discussionmentioning

confidence: 99%

Prediction model for short-term mortality after palliative radiotherapy for patients having advanced cancer: a cohort study from routine electronic medical data

Lee

Luk

Wong

et al. 2020

Sci Rep

View full text Add to dashboard Cite

We developed a predictive score system for 30-day mortality after palliative radiotherapy by using predictors from routine electronic medical record. Patients with metastatic cancer receiving first course palliative radiotherapy from 1 July, 2007 to 31 December, 2017 were identified. 30-day mortality odds ratios and probabilities of the death predictive score were obtained using multivariable logistic regression model. Overall, 5,795 patients participated. Median follow-up was 39.6 months (range, 24.5-69.3) for all surviving patients. 5,290 patients died over a median 110 days, of whom 995 (17.2%) died within 30 days of radiotherapy commencement. The most important mortality predictors were primary lung cancer (odds ratio: 1.73, 95% confidence interval: 1.47-2.04) and log peripheral blood neutrophil lymphocyte ratio (odds ratio: 1.71, 95% confidence interval: 1.52-1.92). The developed predictive scoring system had 10 predictor variables and 20 points. The cross-validated area under curve was 0.81 (95% confidence interval: 0.79-0.82). The calibration suggested a reasonably good fit for the model (likelihood-ratio statistic: 2.81, P = 0.094), providing an accurate prediction for almost all 30-day mortality probabilities. The predictive scoring system accurately predicted 30-day mortality among patients with stage iV cancer. oncologists may use this to tailor palliative therapy for patients.Many patients with metastatic cancer receive oncological treatment, and radiotherapy (RT) is an important component of palliative treatment 1 . RT can be an effective tool for palliation of symptoms arising from cancer, including pain from bone metastases or neurological compromise from brain or spinal metastases with cord or nerve root compression. The aim of palliative RT is to alleviate symptoms and improve quality of life. Evidence has shown that palliative RT was received by approximately 10% of patients who died of cancer near their end of life 2,3 . In one population-based study that included 15,287 patients who received RT in the last month of life, 17.8% received more than 10 days of treatment 4 . This finding corroborates with a German study which showed 50% of patients spent more than 60% of remaining 30 days of life receiving RT 4 .RT can be delivered via different dosing regimens (e.g., single fraction on one day versus multiple fractions for weeks) 5-9 . The use of multi-fractionation (split up the total dose into small fractions) is often perceived to be associated with less long-term complications and need for retreatment 4 . While larger fraction size by single-fractionation theoretically has an increased risk of late-onset radiation toxicity. Beside radiobiological consideration, medical training and experience, departmental policies, and insurance reimbursement all influence the decision on the dose-fractionation regimens. Use of hypofractionation or single fractionation is associated with a perceived poor prognosis by the oncologist. Protracted courses of RT can become considerable demand and burden on termina...

show abstract

“…Rapid progression and high metastatic ability associate with worse survival in patients with HCC (18,19). Apoptosis negatively regulates tumor progression through extrinsic/ intrinsic apoptotic signaling transduction-induced cell death.…”

Section: Discussionmentioning

confidence: 99%

ERK/AKT Inactivation and Apoptosis Induction Associate With Quetiapine-inhibited Cell Survival and Invasion in Hepatocellular Carcinoma Cells

Lee

Chung

Tan

et al. 2020

In Vivo

View full text Add to dashboard Cite

Background/Aim: Quetiapine, an atypical antipsychotic, has been encountered as a potential protective agent to suppress various types of tumor growth. However, the inhibitory mechanism of quetiapine in hepatocellular carcinoma (HCC) still remains unclear. The purpose of present study was to investigate the inhibitory mechanism of quetiapine on cell survival and invasion in HCC. Materials and Methods: Changes of apoptotic signaling, migration/invasion ability, and signaling transduction involved in cell survival and invasion were evaluated with flow cytometry, migration/invasion, and western blot assays. Results: Quetiapine inhibited cell proliferation and migration/invasion in SK-Hep1 and Hep3B cells. Quetiapine induced extrinsic and intrinsic apoptotic pathways. Activation of extracellular signal-regulated kinases (ERK), protein kinase B (AKT), nuclear factor kappa-lightchain-enhancer of activated B cells (NF-ĸB), expression of anti-apoptotic, and metastasis-associated proteins were decreased by quetiapine. Conclusion: The apoptosis induction, the decreased expression of ERK/AKT-mediated anti-apoptotic and the metastasis-associated proteins were associated with quetiapine-inhibited cell survival and invasion in HCC in vitro. Antipsychotic medications are used for the treatment of patients with schizophrenia and other psychotic disorders (1). Recent epidemiological studies have focused on the relationship between cancer risk and the long-term use of antipsychotic drugs in patients with schizophrenia. Long-term antipsychotic treatment did not influence breast cancer risk, whereas risk of gastric or hepatocellular carcinoma (HCC) was reduced with antipsychotic use (2-4). Antipsychotic drugs have been shown to elicit anticancer response in various cancers. Sertindole, the second-generation antipsychotic drug, was presented to induce autophagyassociated apoptosis leading to tumor growth inhibition in breast cancer (5). Aripiprazole, the partial dopamine agonist used for treatment of schizophrenia, not only promoted cell growth inhibition but also increased sensitivity to chemotherapeutic agents in cancer stem cells (6). Quetiapine, the atypical antipsychotic, augments release of neurotransmitters leading to improvement of schizophrenia-negative symptoms (7). In addition to antipsychotic effect, quetiapine as the multifunctional agent has been demonstrated to modulate several biological properties such as anti-inflammation, neuroprotection, and anti-cancer effect (4, 8, 9). Quetiapine was presented to upregulate differentiation of glioma stem cells and enhance anti-glioma efficacy of temozolomide (TMZ) (10). Quetiapine also attenuated breast cancer-induced osteolysis through blocking differentiation of osteoclasts (11). Chen et

show abstract

The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis

Cited by 9 publications

References 35 publications

A practical nomogram from the SEER database to predict the prognosis of hepatocellular carcinoma patients with lymph node metastasis

A practical nomogram from the SEER database to predict the prognosis of hepatocellular carcinoma patients with lymph node metastasis

Prediction model for short-term mortality after palliative radiotherapy for patients having advanced cancer: a cohort study from routine electronic medical data

ERK/AKT Inactivation and Apoptosis Induction Associate With Quetiapine-inhibited Cell Survival and Invasion in Hepatocellular Carcinoma Cells

Contact Info

Product

Resources

About